Literature DB >> 21244860

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions.

Junmin Zhou1, Jinfeng Wu, Xianghong Chen, Nicole Fortenbery, Erika Eksioglu, Krithika N Kodumudi, Epling-Burnette Pk, Jingcheng Dong, Julie Y Djeu, Sheng Wei.   

Abstract

3, 5,7-trihydroxy-4'-methoxy-8-(3-hydroxy-3-methylbutyl)-flavone (ICT) is a novel derivative of Icariin (ICA), the major active ingredient of Herba Epimedii, a herb used in traditional Chinese and alternative medicine. We previously demonstrated its anti-inflammatory effect in murine innate immune cells and activated human PBMCs. We report herein that ICA or ICT treatment reduces the expression of MRP8/MRP14 and toll-like receptor 4 (TLR4) on human PBMCs. Administration of ICA or ICT inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC numbers in the spleen of these mice. Further, we saw a restoration of IFN-γ production by CD8+ T cells in tumor bearing mice when treated with ICA or ICT. ICA and ICT significantly decreased the amounts of nitric oxide and reactive oxygen species in MDSC in vivo. When MDSC were treated in vitro with ICT, we saw a significant reduction in the percent of these cells with concomitant differentiation into dendritic cells and macrophages. Concomitant with this cell type conversion was a down-regulation of IL-10, IL-6 and TNF-α production. Decreased expression of S100A8/9 and inhibition of activation of STAT3 and AKT may in part be responsible for the observed results. In conclusion, our results showed that ICA, and more robustly, ICT, directly modulate MDSC signaling and therefore altered the phenotype and function of these cells, in vitro and in vivo.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21244860      PMCID: PMC3109231          DOI: 10.1016/j.intimp.2011.01.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  40 in total

Review 1.  Alarmins: chemotactic activators of immune responses.

Authors:  Joost J Oppenheim; De Yang
Journal:  Curr Opin Immunol       Date:  2005-08       Impact factor: 7.486

2.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Authors:  Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

3.  Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats.

Authors:  J Guo; F Li; Q Wu; Q Gong; Y Lu; J Shi
Journal:  Phytomedicine       Date:  2010-04-09       Impact factor: 5.340

4.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

Review 5.  Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock.

Authors:  Wen-Jye Lin; Wen-Chen Yeh
Journal:  Shock       Date:  2005-09       Impact factor: 3.454

6.  Optimization for quantitative determination of four flavonoids in Epimedium by capillary zone electrophoresis coupled with diode array detection using central composite design.

Authors:  J J Liu; S P Li; Y T Wang
Journal:  J Chromatogr A       Date:  2005-12-06       Impact factor: 4.759

Review 7.  Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease.

Authors:  Lynn L Stoll; Gerene M Denning; Neal L Weintraub
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 8.  S100A8 and S100A9 in inflammation and cancer.

Authors:  Christoffer Gebhardt; Julia Németh; Peter Angel; Jochen Hess
Journal:  Biochem Pharmacol       Date:  2006-07-17       Impact factor: 5.858

9.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.

Authors:  Cesar A Corzo; Thomas Condamine; Lily Lu; Matthew J Cotter; Je-In Youn; Pingyan Cheng; Hyun-Il Cho; Esteban Celis; David G Quiceno; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

10.  Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.

Authors:  R F Johansen; B Sørensen; J Ingerslev
Journal:  Haemophilia       Date:  2006-03       Impact factor: 4.287

View more
  46 in total

1.  Chemoimmunomodulation of MDSCs as a novel strategy for cancer therapy.

Authors:  Julie Djeu; Sheng Wei
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Icariin Ameliorates Amyloid Pathologies by Maintaining Homeostasis of Autophagic Systems in Aβ1-42-Injected Rats.

Authors:  Xia Jiang; Lin-Lin Chen; Zhou Lan; Fan Xiong; Xiang Xu; Yang-Yang Yin; Ping Li; Ping Wang
Journal:  Neurochem Res       Date:  2019-10-15       Impact factor: 3.996

3.  Icariin prevents cytokine-induced β-cell death by inhibiting NF-κB signaling.

Authors:  Shao Zhong; Jing Ge; Jiang-Yi Yu
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

Review 4.  Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Authors:  Oana Draghiciu; Joyce Lubbers; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 5.  Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Authors:  Daniel Geh; Jack Leslie; Rob Rumney; Helen L Reeves; Thomas G Bird; Derek A Mann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-12       Impact factor: 46.802

Review 6.  The effect of icariin on immunity and its potential application.

Authors:  Rong Shen; Ju-Hua Wang
Journal:  Am J Clin Exp Immunol       Date:  2018-06-05

7.  Up-regulation of long non-coding RNA CYTOR induced by icariin promotes the viability and inhibits the apoptosis of chondrocytes.

Authors:  Guoyou Wang; Lei Zhang; Huarui Shen; Qi Hao; Shijie Fu; Xia Liu
Journal:  BMC Complement Med Ther       Date:  2021-05-26

8.  Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD.

Authors:  Brent H Koehn; Asim Saha; Cameron McDonald-Hyman; Michael Loschi; Govindarajan Thangavelu; Lie Ma; Michael Zaiken; Josh Dysthe; Walker Krepps; Jamie Panthera; Keli Hippen; Stephen C Jameson; Jeffrey S Miller; Matthew A Cooper; Christopher J Farady; Takao Iwawaki; Jenny P-Y Ting; Jonathan S Serody; William J Murphy; Geoffrey R Hill; Peter J Murray; Vincenzo Bronte; David H Munn; Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2019-11-07       Impact factor: 25.476

9.  Myeloid derived suppressor cells: Targets for therapy.

Authors:  Todd J Waldron; Jon G Quatromoni; Tatiana A Karakasheva; Sunil Singhal; Anil K Rustgi
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival.

Authors:  Nagi B Kumar; Medha Dhurandhar; Bharat Aggarwal; Shrikant Anant; Kenyon Daniel; Gary Deng; Julie Djeu; Jinhui Dou; Ernest Hawk; B Jayaram; Libin Jia; Rajendra Joshi; Madhuri Kararala; Devarajan Karunagaran; Omer Kucuk; Lalit Kumar; Mokenge Malafa; G J Samathanam; Fazlul Sarkar; Maqsood Siddiqi; Rana P Singh; Anil Srivastava; Jeffrey D White
Journal:  Cancer Med       Date:  2013-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.